Astatine-211 is an isotope of the chemical element astatine (symbol: At) characterized by extremely high radioactivity. Its half-life is 7.2 hours, making it a relatively long-lived astatine isotope. Astatine-211 is an alpha particle emitter that continuously releases alpha particles consisting of two protons and two neutrons. The chemical properties of astatine resemble those of other halogens, such as iodine, but the radioactivity of astatine-211 greatly limits the study of its chemical properties. It can be used to form chemical bonds with metal organic derivatives (such as tin) or carborane precursors, combined with molecular carriers targeting malignant tumor cell groups, to prepare alpha nuclide targeted therapeutic drugs.

According to the market research report “Global Astatine-211 Market Report 2024–2030” published by QYResearch, the global astatine-211 market is projected to attain a valuation of USD 0.04 billion by 2030, expanding at a compound annual growth rate of 4.9% throughout the forecast period. This exceptionally small absolute size—measured in tens of millions of dollars—belies the isotope‘s strategic significance: astatine-211 is one of the very few alpha-emitting nuclides with decay characteristics suitable for targeted alpha therapy (TAT), and its market trajectory is determined less by demand than by the pace at which production infrastructure can be built. The astatine-211 market is being reshaped by three intersecting forces: the formation of industrial-scale production joint ventures in Europe and the United States, the maturation of first-in-human clinical evidence across multiple cancer indications, and the persistent scarcity of medium-energy alpha-beam cyclotrons capable of generating the 28–29 MeV beams required for production.

Competitive Landscape and Market Concentration

The competitive structure of the astatine-211 market differs fundamentally from conventional isotope categories. Production is currently concentrated among a small number of academic and institutional cyclotron facilities, with commercial supply chains only now beginning to form. QYResearch identifies key players including Ionetix, NIDC (DOE IP), Alpha Fusion, and RIKEN, with the top three holding approximately 99% of supply and the United States constituting the largest market at approximately 97% share . These figures reflect the market’s current state: production is dominated by a handful of facilities serving research and early-phase clinical trials, and commercial-scale distribution remains nascent.

The most consequential recent development is the formation of Ekalia, a joint venture between IBA (Ion Beam Applications) and Framatome, announced in October 2026. Ekalia will deploy a network of astatine-211 production sites close to clinical customers, with the first site planned in Nantes, France, representing an investment of approximately €30 million (USD 33.6 million). The permit application has been submitted, construction is anticipated in early 2027, and operations are expected in 2028 . A second pilot site is planned in the United States. IBA contributes its cyclotron and isotope production technologies, while Framatome contributes nuclear industrial expertise including experience with large-scale lutetium-177 production .

In parallel, Telix Pharmaceuticals announced a collaboration with Ekalia to establish a dedicated U.S. source of astatine-211. The first installation will be an IBA alpha-beam cyclotron at Telix’s RLS Radiopharmacies site near Philadelphia, supporting Telix‘s alpha therapy pipeline including TLX102-Tx for glioblastoma and leptomeningeal disease, while also providing capacity for third-party academic and industry programs .

In Japan, Sumitomo Heavy Industries is establishing commercial supply from the University of Osaka’s TAT Cyclotron Building, housing the world’s first dedicated astatine-211 production cyclotron (MP-30X). The facility features the world‘s highest He²⁺ beam intensity at 200 microamperes and is scheduled to commence operations in fiscal 2027. Sumitomo will distribute astatine-211 commercially to customers including Alpha Fusion, which is initiating Phase I trials in 2026 .

Technical Differentiation: Production Route and the Cyclotron Bottleneck

The production of astatine-211 is achieved through the ²⁰⁹Bi(α,2n)²¹¹At reaction, bombarding natural bismuth targets with alpha particles at energies of approximately 28 MeV . The threshold energy for this reaction is 22 MeV, with the optimal bombardment range established between 22 and 28 MeV to maximize astatine-211 yield while minimizing contaminants including At-210 and Po-210 . The production route is relatively straightforward compared with other alpha emitters, but the isolation of microscopic quantities of astatine-211 from massive bismuth targets within a few hours of end-of-bombardment imposes stringent radiochemical requirements .

The critical bottleneck is accelerator availability. Astatine-211 production requires cyclotrons capable of generating 28–29 MeV alpha-particle beams, a specification that few facilities worldwide possess. A 2024 survey identified approximately 15 facilities producing astatine-211 globally, concentrated in Europe and North America . European producing sites include Rigshospitalet in Denmark with batch sizes of approximately 3 GBq, GIP Arronax in France at approximately 2 GBq, and Forschungszentrum Jülich in Germany at approximately 5.6 GBq, with 50 to 200 batches per year depending on the facility . The limited number of suitable accelerators is the single most significant factor constraining supply .

The short half-life of 7.2 hours compounds the supply constraint: astatine-211 must be produced close enough to clinical facilities to keep transportation time short, precluding centralized production and long-distance distribution. This geographic constraint explains Ekalia‘s network model of distributed production sites rather than a single large facility . Sumitomo‘s capacity analysis illustrates the scale economics: at less than 400 MBq per patient, a single irradiation could treat more than 6.5 patients, and with two irradiations per day over 240 days, a total of 3,120 treatments per year would be possible at one facility .

Clinical Validation: First-in-Human Evidence Across Multiple Indications

The most significant recent development in astatine-211‘s clinical trajectory is the publication of first-in-human trial results across multiple cancer indications. In October 2026, the Journal of Clinical Oncology published results from a first-in-human, two-stage dose-finding trial evaluating ²¹¹At-BC8-B10, an anti-CD45 radioimmunotherapy, before conditioning with fludarabine and low-dose total body irradiation and allogeneic hematopoietic cell transplantation in adults with high-risk hematologic malignancies. The trial, conducted at the Fred Hutchinson Cancer Center, represents the first clinical evaluation of an astatine-211-labeled antibody in this setting . The rationale is compelling: CD45 is uniformly and abundantly expressed on almost all normal and neoplastic hematopoietic cells, and alpha particles offer more potent and precise target cell killing than beta emitters, inducing complex DNA damage that may enhance cytotoxicity in otherwise radioresistant disease .

In Japan, the University of Osaka has completed first-in-human investigator-initiated clinical trials using [²¹¹At]sodium astatide for metastatic thyroid cancer refractory to radioiodine therapy, observing disappearance of iodine-avid lesions and marked reduction in serum thyroglobulin levels. A clinical trial of a PSMA-targeting astatine-211 compound for castration-resistant prostate cancer is also underway, with study completion targeted for 2027 .

Market Drivers: Unmet Clinical Need and Targeted Alpha Therapy Promise

The principal demand driver for astatine-211 is its suitability for targeted alpha therapy in microcancers undetectable by traditional methods. Alpha particles deposit highly concentrated radiation over a very short distance—typically a few cell diameters—enabling selective killing of cancer cells while minimizing exposure to healthy tissue . This physical characteristic makes astatine-211 particularly attractive for minimal residual disease, micrometastases, and disseminated malignancies where beta emitters deliver insufficient dose to small tumor deposits.

The second driver is the strengthening of international cooperation in astatine-211 research and production. The World Astatine Community (WAC) has been formed, bringing together the European NOAR network, the American network (US DOE and Canada), the Asian network (Japan, China, and Korea), and the African network to enhance scientific research, expand global production capacity, and stimulate clinical interest . In Europe, the ACCELERATE.EU project, funded by EU-HORIZON-JU-IHI, brings together 17 partners across Europe with expertise in astatine-211 and targeted alpha therapies, aiming to establish distributed production networks, harmonized practices, and structured workforce training .

The third driver is government and institutional support for nuclear medicine and radioisotope research. In Japan, the TAT Cyclotron Building was funded by the Ministry of Economy, Trade and Industry (METI), representing a national commitment to establishing astatine-211 supply infrastructure . In the United States, the Department of Energy is enhancing astatine-211 production at existing cyclotrons and using the DOE IP network for nationwide distribution .

Market Restraints: Supply Chain Complexity and Regulatory Fragmentation

The principal restraint on the astatine-211 market is supply chain complexity. The production, purification, and labeling of astatine-211 require close cooperation across multiple links—cyclotron operation, target processing, radiochemical separation, and radiolabeling—and errors in any link can affect final application efficacy. The short half-life leaves no margin for delays, and the absence of a stable isotope complicates quality verification: confirming that the product is genuinely astatine-211 or an astatine-labeled compound is not straightforward, requiring gamma spectrometry or mass spectrometry for identity confirmation .

A second restraint is regulatory fragmentation. The use of radioactive isotopes is subject to strict regulatory policy restrictions, and policies for astatine-211 differ across countries and regions, increasing the difficulty of cross-border application. European analyses identify regulatory complexity as a self-reinforcing barrier linked to limited supply and restricted clinical evidence generation: without sufficient supply, clinical trials cannot proceed; without clinical evidence, regulators lack the basis for approval; and without approval, investment in production capacity remains uncertain .

A third consideration is economic uncertainty. Although astatine-211 has potential application value in cancer treatment, its economic benefits require further evaluation. The long R&D cycle, large investment, and high risk create uncertainty for investors assessing commercial viability. The high production cost translates to a high market price, which limits application in economically underdeveloped regions.

Challenges: Radiochemistry and Workforce Readiness

Astatine‘s multiple oxidation states (–1, 0, +1, +3, +5), sensitivity to solvent and redox conditions, and susceptibility to alpha-induced radiolysis pose specific technical challenges in processing. Achieving reproducible speciation control at tracer levels, preventing radiolytic oxidation or reduction during high-activity processing, and ensuring consistent stability of astatine-vector bonds remain incompletely resolved . Current mitigation strategies rely on controlled redox environments, radical scavengers, and rapid automated syntheses, but full control of astatine speciation remains elusive.

Workforce readiness constitutes a parallel challenge. The specialized knowledge required for cyclotron operation, radiochemical processing, and quality control is concentrated among a small number of experts, and the expansion of production capacity depends on training sufficient personnel to staff new facilities. European analyses explicitly identify insufficient workforce readiness as a component of the self-reinforcing barrier dynamic .

Regional Dynamics and Strategic Implications

Japan occupies a leading position in astatine-211 clinical translation, anchored by the University of Osaka‘s long-standing research program, the first-in-human thyroid and prostate cancer trials, and the forthcoming TAT Cyclotron Building with Sumitomo Heavy Industries‘ commercial distribution . Europe is building industrial infrastructure through Ekalia’s Nantes facility and the ACCELERATE.EU consortium, while the United States is pursuing a dual-track approach of DOE-supported academic production and commercial partnership through Telix and Ekalia . China is developing domestic capability through Sichuan University and the forthcoming Alpha Nuclide (Zhejiang) facility .

For stakeholders across the value chain, the strategic imperatives are clear. Radiopharmaceutical developers should secure long-term supply agreements with emerging production networks before clinical demand outpaces capacity, recognizing that the 7.2-hour half-life makes geographic proximity to production sites a non-negotiable site-selection criterion. Cyclotron operators and equipment suppliers should prioritize the deployment of dedicated alpha-beam accelerators optimized for astatine-211 production, as the shortage of suitable machines is the binding constraint on market growth. Investors should monitor two variables as leading indicators: the operational start dates of Ekalia‘s Nantes facility and Sumitomo’s Osaka supply, which will determine whether clinical trial demand can be met through 2028, and the publication of Phase I dose-escalation results across the CD45, PSMA, and thyroid indications, which will determine whether astatine-211 transitions from academic curiosity to commercially viable therapeutic platform.

The astatine-211 market is not a growth category in conventional terms—its USD 0.04 billion valuation reflects the infancy of the field rather than its potential—but it is a clinically consequential one: as long as alpha-emitting radionuclides offer the prospect of precise, potent cancer cell killing with minimal collateral damage, the isotope that best combines favorable decay characteristics with scalable production will remain a specification of consequence in the radiopharmaceutical industry‘s therapeutic roadmap.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp